Table of Contents Author Guidelines Submit a Manuscript
Volume 2012, Article ID 740279, 11 pages
Clinical Study

Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study

1Department of Hematology, Oncology and Palliative Care, Sarcoma Center Berlin-Brandenburg, HELIOS Klinikum Bad Saarow, 15526 Bad Saarow, Germany
2Department of Medical Oncology, Christie Hospital, Wilmslow Road, Withington, Manchester M 204 BX, UK
3Medical Oncology Unit, Institut Català d'Oncologia, Gran Via, s/n km 2,7, 08907 L'Hospitalet de Llobregat, Barcelona, Spain
4Sezione di Chemioterapia dei Tumori dell’Apparato Locomotore, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
5Hospital Son Dureta, Andrea Doria 55, 07014 Palma de Mallorca, Spain
6Department of Clinical Oncology, Leiden University Medical Center (LUMC), Albinusdreef 2, 2333 ZA Leiden, The Netherlands
7Health Economic Statistics, Merck Research Laboratories, Upper Gwynedd, PA 19454, USA
8Global Health Outcomes, Merck Research Laboratories, Whitehouse Station, NJ 08889, USA
9Ingenix Pharmaceutical Services AB, Optum Insight, Klarabergsviadukten 90, Hus D, 11164 Stockholm, Sweden
10Pennsylvania Hematology Oncology Associates, 230 West Washington Square, 2nd Floor, Philadelphia, PA 19106, USA
11Department of Medical Oncology, University Claude Bernard Lyon I, 43 Boulevard du 11 Novembre 1918, 69622 Villeurbanne cedex, Lyon, France

Received 15 November 2011; Accepted 23 December 2011

Academic Editor: Charles Scoggins

Copyright © 2012 Peter Reichardt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The aim of the study was to assess health-related quality of life (HRQoL) among metastatic soft tissue (mSTS) or bone sarcoma (mBS) patients who had attained a favourable response to chemotherapy. We employed the EORTC QLQ-C30, the 3-item Cancer-Related Symptoms Questionnaire, and the EQ-5D instrument. HRQoL was evaluated overall and by health state in 120 mSTS/mBS patients enrolled in the SABINE study across nine countries in Europe and North America. Utility was estimated from responses to the EQ-5D instrument using UK population-based weights. The mean EQ-5D utility score was 0.69 for the pooled patient sample with little variation across health states. However, patients with progressive disease reported a clinically significant lower utility (0.56). Among disease symptoms, pain and respiratory symptoms are common. This study showed that mSTS/mBS is associated with reduced HRQoL and utility among patients with metastatic disease.